Skip to content

Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy

Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neo-adjuvant Therapy : a Prospective Randomized Control Trial.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05838001
Enrollment
110
Registered
2023-05-01
Start date
2023-02-16
Completion date
2025-12-01
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast-conserving Surgery

Brief summary

The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs. combined breast tissue markers in localizing non-palpable breast cancer.

Interventions

Positioning guide wire and marker clip in the center of the breast lesion

PROCEDUREmarker clip localization

Positioning marker clip in the center of the breast lesion

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. female patients, age≥18 year 2. A score of ≥ 2 on the Eastern Cooperative Oncology Group scale 3. Patients pathologically diagnosed with breast cancer by core-needle biopsy, received neoadjuvant treatment and the lesion becomes non-palpable before enrollment. 4. Patients are willing to undergo breast conserving surgery and have no contraindications to breast conserving surgery

Exclusion criteria

1. Inflammatory breast cancer or Paget's disease 2. Breast deformities and other conditions that impact breast conservation success rate 3. Patients with contraindications to breast-conserving surgery, as well as those with systemic diseases, mental disorders, or other subjective reasons that may affect their ability to participate in the trial. Patients with severe bleeding disorders or coagulation disorders were also excluded. 4. Pregnancy or lactation 5. Patients with hook-wire, radioactive 125I seed or other localization techniques in the breast cancer lesions before enrollment 6. Patients with stage IV diseases or unresectable lesions in either breast 7. Patients combined with other diseases that may affect survival 8. Patients with multicentric breast cancer lesions or lesions \> 5 cm in diameter on imaging examinations 9. Patients who have previously undergone radical mastectomy for ipsilateral breast cancer or chest wall radiotherapy 10. Patients with history of ipsilateral breast cancer radical mastectomy or chest wall radiotherapy

Design outcomes

Primary

MeasureTime frameDescription
Marginal positive rateup to 3 monthsProportion of patients with positive margin (intraoperative freezing and postoperative pathological margin tissue showing cancer)

Secondary

MeasureTime frameDescription
Re-operation rate.up to 3 monthsthe proportion of patients which have a positive margin and requires a re-operation
The proportion of breast-conserving surgery.up to 3 monthsIt refers to the proportion of patients who have successfully undergone breast-conserving surgery.
IDFS2 years, 3 years, and 5 yearsTime from surgery to the first occurrence of local, distant disease recurrence, or death.

Countries

China

Contacts

Primary ContactChang Gong, doctor
changgong282@163.com02034070499

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026